Last reviewed 2026-04-22 · How we verify

Zofran inj.+Zofran tab.

Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.

At a glance

Mechanism of action

Ondansetron is a selective 5-HT3 receptor antagonist that works centrally and peripherally to inhibit signals that trigger the vomiting reflex. It is particularly effective against chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV) by blocking serotonin signaling in the chemoreceptor trigger zone and on vagal afferent fibers in the gastrointestinal tract.

Approved indications

• Chemotherapy-induced nausea and vomiting (CINV)
• Post-operative nausea and vomiting (PONV)
• Radiation-induced nausea and vomiting

Common side effects

• Headache
• Constipation
• Diarrhea
• Fatigue
• Dizziness
• Fever

Key clinical trials

• Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery (NA)
• Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Zofran inj.+Zofran tab. CI brief — competitive landscape report
• Zofran inj.+Zofran tab. updates RSS · CI watch RSS
• LG Life Sciences portfolio CI